Best of the Week
Most Popular
1. Investing in a Bubble Mania Stock Market Trending Towards Financial Crisis 2.0 CRASH! - 9th Sep 21
2.Tech Stocks Bubble Valuations 2000 vs 2021 - 25th Sep 21
3.Stock Market FOMO Going into Crash Season - 8th Oct 21
4.Stock Market FOMO Hits September Brick Wall - Evergrande China's Lehman's Moment - 22nd Sep 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
7.AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
8.Why Silver Price Could Crash by 20%! - 5th Oct 21
9.Powell: Inflation Might Not Be Transitory, After All - 3rd Oct 21
10.Global Stock Markets Topped 60 Days Before the US Stocks Peaked - 23rd Sep 21
Last 7 days
Stock Market Investing LESSON - Buying Value - 27th Nov 21
Corsair MP600 NVME M.2 SSD 66% Performance Loss After 6 Months of Use - Benchmark Tests - 27th Nov 21
Stock Maket Trading Lesson - How to REALLY Trade Markets - 26th Nov 21
SILVER Price Trend Analysis - 26th Nov 21
Federal Reserve Asks Americans to Eat Soy “Meat” for Thanksgiving - 26th Nov 21
Is the S&P 500 Topping or Just Consolidating? - 26th Nov 21
Is a Bigger Drop in Gold Price Just Around the Corner? - 26th Nov 21
Financial Stocks ETF Sector XLF Pullback Sets Up A New $43.60 Upside Target - 26th Nov 21
A Couple of Things to Think About Before Buying Shares - 25th Nov 21
UK Best Fixed Rate Tariff Deal is to NOT FIX Gas and Electric Energy Tariffs During Winter 2021-22 - 25th Nov 21
Stock Market Begins it's Year End Seasonal Santa Rally - 24th Nov 21
How Silver Can Conquer $50+ in 2022 - 24th Nov 21
Stock Market Betting on Hawkish Fed - 24th Nov 21
Stock Market Elliott Wave Trend Forecast - 24th Nov 21
Your once-a-year All-Access Financial Markets Analysis Pass - 24th Nov 21
Did Zillow’s $300 million flop prove me wrong? - 24th Nov 21
Now Malaysian Drivers Renew Their Kurnia Car Insurance Online With Fincrew.my - 24th Nov 21
Gold / Silver Ratio - 23rd Nov 21
Stock Market Sentiment Speaks: Can We Get To 5500SPX In 2022? But 4440SPX Comes First - 23rd Nov 21
A Month-to-month breakdown of how Much Money Individuals are Spending on Stocks - 23rd Nov 21
S&P 500: Rallying Tech Stocks vs. Plummeting Oil Stocks - 23rd Nov 21
Like the Latest Bond Flick, the US Dollar Has No Time to Die - 23rd Nov 21
Why BITCOIN NEW ALL TIME HIGH Changes EVERYTHING! - 22nd Nov 21
Cannabis ETF MJ Basing & Volatility Patterns - 22nd Nov 21
The Most Important Lesson Learned from this COVID Pandemic - 22nd Nov 21
Dow Stock Market Trend Analysis - 22nd Nov 21
UK Covid-19 Booster Jabs Moderna, Pfizer Are They Worth the Risk of Side effects, Illness? - 22nd Nov 21
US Dollar vs Yields vs Stock Market Trends - 20th Nov 21
Inflation Risk: Milton Friedman Would Buy Gold Right Now - 20th Nov 21
How to Determine if It’s Time for You to Outsource Your Packaging Requirements to a Contract Packer - 20th Nov 21
2 easy ways to play Facebook’s Metaverse Spending Spree - 20th Nov 21
Stock Market Margin Debt WARNING! - 19th Nov 21
Gold Mid-Tier Stocks Q3’21 Fundamentals - 19th Nov 21
Protect Your Wealth From PERMANENT Transitory Inflation - 19th Nov 21
Investors Expect High Inflation. Golden Inquisition Ahead? - 19th Nov 21
Will the Senate Confirm a Marxist to Oversee the U.S. Currency System? - 19th Nov 21
When Even Stock Market Bears Act Bullishly (What It May Mean) - 19th Nov 21
Chinese People do NOT Eat Dogs Newspeak - 18th Nov 21
CHINOBLE! Evergrande Reality Exposes China Fiction! - 18th Nov 21
Kondratieff Full-Season Stock Market Sector Rotation - 18th Nov 21
What Stock Market Trends Will Drive Through To 2022? - 18th Nov 21
How to Jump Start Your Motherboard Without a Power Button With Just a Screwdriver - 18th Nov 21
Bitcoin & Ethereum 2021 Trend - 18th Nov 21
FREE TRADE How to Get 2 FREE SHARES Fractional Investing Platform and ISA Specs - 18th Nov 21
Inflation Ain’t Transitory – But the Fed’s Credibility Is - 18th Nov 21
The real reason Facebook just went “all in” on the metaverse - 18th Nov 21
Biden Signs a Bill to Revive Infrastructure… and Gold! - 18th Nov 21
Silver vs US Dollar - 17th Nov 21
Silver Supply and Demand Balance - 17th Nov 21
Sentiment Speaks: This Stock Market Makes Absolutely No Sense - 17th Nov 21
Biden Spending to Build Back Stagflation - 17th Nov 21
Meshing Cryptocurrency Wealth Generation With Global Fiat Money Demise - 17th Nov 21
Dow Stock Market Trend Forecast Into Mid 2022 - 16th Nov 21
Stock Market Minor Cycle Correcting - 16th Nov 21
The INFLATION MEGA-TREND - Ripples of Deflation on an Ocean of Inflation! - 16th Nov 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Could This Be The Hottest Investment Sector For 2021?

Companies / BioTech May 18, 2021 - 12:56 PM GMT

By: FinancialMorningPost

Companies

A $52-billion pain management market, a $14-billion antidepressant market, and a  $4.5 trillion global wellness market are all coming together to make what could be a mega opportunity for a segment that few can ignore anymore…

That segment is psychedelics… and it could be a game-changer for the mental health of our nation.

The convergence of these three mega markets could well end up being bigger--and better--than cannabis.

Psychedelics are emerging as a possible solution for pain management and multiple mental health issues.

It’s got nothing to do with recreation.


This is science and drug development for some of the biggest medical challenges of our time.
But we think the real story is what’s going on behind the scene, where a little-known cultivation and extraction innovator may be emerging as a supplier of some of the underlying product to labs and retailers that hope this will be the next big thing in wellness.

The little-known company is HAVN Life (CSE: HAVN; OTC: HAVLF) and we think its entrance into the public market couldn’t have come at a better time. In a post-pandemic world, where opioids, antidepressants, PTSD treatments, and immunity-boosting supplements may see demand soar - a natural alternative could be exactly what the market needs.

COVID-19 cases and deaths may be starting to decline in some places around the world, but the scars left behind by the pandemic will be deep. We think it’s time for a new therapy--and it’s not another addictive opioid. It’s science and nature, and the stigma could be slowly melting away.  

One Disrupting Compound. Two Revenue Verticals

Psilocybin is the active ingredient in magic mushrooms, and its possible fast-track commercialization is what this is all about …

It’s not about Big Pharma, which has struggled to positively tackle mental health. It’s about a new and natural approach, one that may help deal with issues like depression, which is the number one cause of disability and ill-health in the U.S. 

Even the FDA calls psilocybin a “breakthrough therapy”.

And HAVN Life is what happens when two major names in the cannabis industry get together to harness what may be the next major wellness trend for shareholders.

Remember Aphria (NYSE:APHA)? Remember its valuation increase of over 2,300%?

Some of those same people look like they’re planning to do it again, this time with psilocybin.

Vic Neufeld and Gary Leong, both founders of Canadian cannabis darling Aphria (NYSE:APHA), are helping to pioneer the new industry.

Together, they’ve developed a global community in support of “microdosing” therapy research, extraction, formulation, and delivery to the market. And their work with veterans and the military, especially in the area of PTSD, is fast making them a new industry standard.

Neufeld is the former CEO of Aphria and the former CEO of Jamieson Wellness (TSX:JWEL), which he built into a leader in vitamins and botanical medicines during his 21 years at the helm.

And now, HAVN Life (CSE: HAVN; OTC: HAVLF) has brought on Gary Leong, a highly sought-after chemist who was the former Chief Scientific Officer at Aphria and another 14-year veteran of Jamieson Wellness. Leong has also served as an advisor to several Canadian government regulatory committees.

Now, coming off the big success at both Aphria and Jamieson, we think they may have mapped out a path to success for HAVN Life.

They’ve got two potential revenue verticals to interest shareholders: Haven Labs and Haven Retail.

Havn Labs is aimed to take advantage of the soaring demand for psilocybin for clinical research, which needs a reliable supply that is safe and of high quality. That’s why HAVN is reported to be spending C$800,000 on a new state-of-the-art mycology laboratory in Vancouver British Columbia.

It’s said to be set to launch this year and will aim to be a premier cultivation and extraction facility for clinical-quality psilocybin. Here, HAVN says it will be able to formulate and produce naturally-derived psychedelics in one location.

There are several hundred studies around the world on psychedelics, but it’s almost all being done using synthetic psilocybin. HAVN saw the opportunity to build a library of naturally derived APIs to support pre-searchers and formulators to provide a safe supply of naturally derived compounds.

They plan to become the standard.

HAVN is in the process of building out supply agreements with researchers that may eventually lead to a supply agreement with experienced names creating commercialized products in this space.

But there may be another vertical here, too, that could be exciting for investors.
HAVN looks to be casting a very wide net around this emerging megatrend.

The consumer wellness market has already reached $4.5 trillion, and HAVN Retail is targeting this with its fungi-based nutraceutical supplements.

HAVN (CSE: HAVN; OTC: HAVLF) says it only takes 60 days to develop a product for market once it’s cleared by Health Canada, which can then be distributed to HAVN Retail’s e-commerce store and retailers around the country.

And demand for supplements is already high--and rising.

The Canadian vitamins and minerals market is valued at $471 million, with 74% of adults taking at least one supplement per year.

The same market in the U.S. is valued at over $7.4 billion.

Mushrooms were the second-highest growing natural health supplement and are underserved in the market. HAVN intends to change that.

And this isn’t just another mushroom. HAVN’s products are reported to rely on specialized extracts rather than whole plants because research has shown that 200mg of mushroom extract has a greater therapeutic effect than 200mg of dried mushrooms.

And what happens next could increase this company’s enterprise value: HAVN announced it has launched preclinical trials to investigate the effects of psilocybin on the immune system--a potentially ground-breaking study that could lead to the development of new medicines.

Look No Further for the Next Megatrend

Psychedelics are set to be the next great health megatrend.

For us, there’s no better indication that this has gone mainstream than this: There is even a psychedelic exchange traded fund (ETF).

Horizons Psychedelic Stock Index ETF (PSYK) began trading on the Canadian NEO exchange in January this year. PSYK will offer investors exposure to a basket of 17 publicly traded companies focused on using psychedelics like LSD to treat mental health issues such as depression, anxiety, obsessive-compulsive disorder, PTSD, and even eating disorders.  

In a milestone for investors, HAVN was one of the 17 companies included in the ETF, bringing more exposure and presumably generating greater value for shareholders.

Psychedelics are an emerging megatrend as much as depression is a pandemic of its own--one that is getting worse due to COVID-19.

The statistics are more than alarming.

And while experts are still waiting for more data, Harvard notes that initial data suggests the coronavirus invades the brain, leaving more than one-third of patients with neurologic symptoms. That’s one-third of 150 million people--just this week.

It’s also worsened mental health conditions overall thanks to isolation, loss and extreme stress.

So, welcome to the psychedelic renaissance that has the global scientific community hungry for new research that shows that compounds such as HAVN’s psilocybin can have “profound mental health benefits” when used in controlled settings.

The decriminalization drive is fully underway, and assuming its success with psychedelics find their way into Big Pharma’s production facilities for depression, anxiety, PTSD, addiction, this may be a $100-billion segment, according to analysts at Eight Capital.

HAVN (CSE: HAVN; OTC: HAVLF) looks to be part of the supply chain that underpins this potential $100-billion segment. It may be part of the backbone of it all.

HAVN isn’t just in this space, it’s a supplier for this space. It’s helping to define this space with a state-of-the-art lab in British Columbia, an entire retail setup, and the cannabis veterans who have already taken a megatrend stock to substantially increased valuations for investors--twice.

By. Jennifer Weybridge

**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Forward-Looking Statements

This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include that the global wellness market will continue to increase and that demand for mushroom based supplements will continue to rise; that the market for nutraceutical mushroom based products will continue to grow; that the market for psychedelic mushrooms will continue to increase for research purposes focused on alternative mental health treatments; that psychedelics will gain regulatory, medical, commercial and social acceptance as a potential treatment for various mental and other illnesses; that HAVN can be a supplier of functional and psychedelic mushroom products; that HAVN can be a leader in scientific research and achieve a new standard in naturally derived psilocybin; that HAVN can successfully build out supply agreements with researches and obtain supply agreements to create commercialized products; that HAVN will develop fungi-based nutraceutical products for the wellness market that will achieve Health Canada approval and be sold on e-commerce sites and by retailers around the country; that HAVN can produce products using specialized extracts which have a greater therapeutic effect for consumers; that psychedelic mushrooms will be decriminalized and gain acceptance as a viable medical treatment for mental illness; that HAVN will develop a state-of-the-art research lab and become a supplier for the psychedelic and functional mushroom markets. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information.  Risks that could change or prevent these statements from coming to fruition include that the global wellness market may not increase as anticipated and that demand for supplements, and in particular mushroom based supplements, may decrease; that the market for nutraceutical mushroom based products may decrease; that the market for psychedelic mushrooms decreases psychedelic mushroom based treatments are found to be dangerous, ineffective or have unwanted side effects; that psychedelics will fail to gain regulatory, medical, commercial and social acceptance as a potential treatment for various mental and other illnesses; that HAVN may be unable to develop its business as a supplier of functional and psychedelic mushroom products; that HAVN may fail to become a leader in scientific research or achieve a new standard in naturally derived psilocybin; that HAVN may fail to achieve supply agreements with researches or obtain supply agreements to create any commercialized products; that HAVN may be unable to successfully develop and manufacture fungi-based nutraceutical products for the wellness market that receive Health Canada approval; even if they do successfully produce products, competitors may offer better and cheaper products; that HAVN’s products may prove not to work at all; that psychedelic mushrooms may not be decriminalized or gain only limited or no acceptance as a viable medical treatment for mental illness; that HAVN mau be unable to develop a state-of-the-art research lab or become a supplier for the psychedelic and functional mushroom markets.. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

DISCLAIMERS

This communication is for entertainment purposes only. Never invest purely based on our communication. FinancialMorningPost.com and its owners and affiliates (“FinancialMorningPost.com”) are being paid ninety thousand USD for this article as part of a larger marketing campaign for CSE:HAVN. The information in this report and on our website has not been independently verified and is not guaranteed to be correct.

SHARE OWNERSHIP. The owner and affiliates of FinancialMorningPost.com own shares of HAVN and therefore have an additional incentive to see the featured company’s stock perform well. FinancialMorningPost.com is therefore conflicted and is not purporting to present an independent report. The owner and affiliates of FinancialMorningPost.com will not notify the market when it decides to buy more or sell shares of this issuer in the market. The owner of FinancialMorningPost.com will be buying and selling shares of this issuer for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. 

NOT AN INVESTMENT ADVISOR. FinancialMorningPost.com is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation, nor are any of its writers or owners.

ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

RISK OF INVESTING. Investing is inherently risky. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any stock acquisition will or is likely to achieve profits.


© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in